cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome
Keyword(s):
We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing’s syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, Folfirinox, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well-correlated with the disease course, and cfDNA may be used as a predictive marker and/or an early marker of response. In addition, absolute count of atypical cells was elevated upon disease progression.
1996 ◽
Vol 19
(3)
◽
pp. 205-208
◽
2016 ◽
Vol 5
(1)
◽
pp. 113-116
◽
Keyword(s):
2008 ◽
Vol 116
(09)
◽
pp. 515-519
◽